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Abstract 
 
Accurate prediction of tumor control and toxicities in radiation therapy faces many 
uncertainties. Besides inter-patient variability in the response to radiation, there are 
also dosimetric uncertainties, i.e. differences between the dose displayed in a 
treatment planning system and the dose actually delivered to the patient. These 
uncertainties originate from several sources including imperfect knowledge of the 
patient geometry, approximation in the physics of radiation interaction with tissues, 
and uncertainties in the biological effectiveness of radiation. Generally, uncertainties 
are considered in the treatment planning process by applying margins. In intensity-
modulated radiotherapy (IMRT), this leads to the planning target volume (PTV) 
concept. Intensity-modulated proton therapy (IMPT) is widely considered as the 
future of proton therapy. The treatment planning methods for IMPT and IMRT are 
similar and based on mathematical optimization techniques for both modalities. 
However, the PTV concept has fundamental limitations in IMPT. Therefore, 
researchers have developed robust optimization methods that directly incorporate 
uncertainties into the IMPT optimization problem. In recent years, vendors of 
commercial planning systems have started to implement these methods so that 
robust IMPT planning becomes available in clinical practice. This article summarizes 
uncertainties in proton therapy and the limitations of the PTV concept to deal with 
them. Subsequently, robust optimization techniques to overcome these limitations 
are reviewed. 
 
 
 
1. Uncertainties in proton therapy planning 
 
Treatment planning in proton therapy faces many uncertainties. The first uncertainty 
in the treatment planning chain is target delineation. Delineation of the gross tumor 
volume (GTV) based on CT, MR and PET imaging is challenging, in part because all 
current imaging modalities only visualize surrogates for the presence of tumor, but 
do not visualize the tumor per se. Delineation of the clinical target volume (CTV), 
which aims to include microscopic tumor infiltration into normal tissues faces even 
larger uncertainty [1] because microscopic tumor cannot be visualized with current 
imaging techniques. Following target delineation, there are also uncertainties in dose 
prescription. There is variability in tumor radiosensitivity between patients as well as 
heterogeneity within the individual patient’s tumor related to genomic and physiologic 
factors. Concepts of biological target volume have been proposed to quantitatively 
consider tumor heterogeneity based on imaging information but are not being used 
routinely in the clinic [2]. While these uncertainties may be the largest in the 
treatment planning chain, they are not specific to proton therapy and thus not the 
topic of this article. Instead this paper will focus on  
• Uncertainties in predicting the physical dose distribution. Here we focus on 
the particle therapy specific problem of range uncertainty. 
• Uncertainties in predicting the biological dose distribution, i.e. the uncertainty 
in predicting the distribution of RBE-weighted dose. 
 
 
1.1 Physics uncertainties in proton therapy 
 
Under the term physics uncertainties, we summarize all uncertainties in predicting 
the physical dose distribution delivered to the patient. Most physical uncertainties 
originate from an imperfect patient model. The most important input to treatment 
planning is the planning CT image, which has several limitations. First, the planning 
CT is only a snapshot of possible patient geometries which may not be reproducible 
in day-to-day treatment due to setup uncertainty, inter-fraction and intra-fraction 
organ motion. Second, the Hounsfield numbers obtained from the planning CT, 
which from a physics perspective display photon attenuation coefficients, are an 
imperfect input for dose calculation algorithms. Not only is there statistical noise in 
CT images, but there are systematic uncertainties because there is no well-defined 
relationship between Hounsfield numbers and tissue properties. Most prominently, 
uncertainty in the conversion of Hounsfield numbers to stopping power for proton 
beams represents a type of uncertainty that is unique for charged particle 
radiotherapy.  
 
Besides uncertainties that arise from an imperfect patient model, additional 
approximations are being made. For example, pencil beam algorithms are being 
applied because of their computational efficiency at the cost of lower accuracy 
compared to Monte Carlo methods. Many of these uncertainties lead to errors in 
predicting the range of protons in a patient and thus the location of the distal dose 
fall-off. These can be on the order of several mm in water equivalent path length 
caused by the conversion from CT image to tissue properties, underestimation of 
scattering by analytical algorithms, and interfaces from low to high density tissues 
parallel to the beam affecting scattering [3, 4]. The impact of uncertainties related to 
imaging, setup, or dose calculation algorithms in proton therapy has been 
extensively studied [5-7]. Consequently, an additional range margin needs to be 
considered in proton therapy to ensure tumor coverage [8]. 
 
Treatment planners have long been aware of uncertainties in proton therapy 
planning and delivery, and consequently devised heuristics to ensure that tumor 
dose prescriptions and organ dose constraints are fulfilled despite errors in planning 
and delivery. Examples of such methods are: 
 
• Choice of beam directions. Typically, it may be possible to minimize potential 
impact of range uncertainties by using a larger number of beam directions. In 
addition, carefully selecting beam angles not to go through regions of day-to-
day anatomical variations or region with large anatomical density variations 
results in more robust plans.  
• In treatment planning for passively scattered proton therapy, range and 
modulation of the spread-out Bragg peak is increased to account for range 
uncertainty. Widening of the aperture and compensator smearing is used to 
account for setup uncertainty. [9, 10] 
 
Pencil beam scanning is gradually replacing passively scattered proton therapy [11, 
12]. IMPT is seen as the future of proton therapy by many researchers and 
practitioners. IMPT uses treatment planning methods that are very similar to those 
used in IMRT planning [13]. For both modalities, clinical planning goals are 
formulated mathematically in terms of objective functions. Subsequently, 
mathematical optimization algorithms are used to determine pencil beam intensities 
that minimize the objective function value and, in that sense, best meet the planning 
goals. 
 
At first glance it may appear logical to also use the same concept for handling 
uncertainty. Delivery uncertainties in IMRT are typically considered by a margin used 
to create a Planning Target Volume (PTV) or, in the case of moving targets, an 
Internal Target Volume (ITV). These margin assignments depend on the treatment 
site and tumor location although general recipes have been suggested [14]. 
However, the PTV concept has significant limitations and shortcomings in IMPT [7, 
15]. The fundamental assumption behind the PTV concept is that the shape of the 
dose distribution is largely unaltered by the underlying changes of the patient 
geometry. Hence, it is assumed that, as long as the CTV moves within the 
boundaries of the PTV, and the PTV is irradiated to the prescribed dose, then the 
CTV is guaranteed to receive the prescribed dose. While this is an acceptable 
assumption in IMRT, it is no longer valid for protons.  
 
This issue is illustrated in figures 1a and 2a for an ependymoma patient, in whom the 
target contains parts of the brainstem. The treatment plan consists of 3 coplanar 
beams and was created using conventional IMPT planning aiming at a prescription 
dose of 50 Gy physical dose (corresponding to 55 Gy(RBE) for a constant RBE of 
1.1). 5% overdose was allowed in those parts of the CTV that do not overlay the 
brainstem. Additional planning objectives were conformity as well as minimizing dose 
to the brainstem and the surrounding healthy tissues. A 2 mm CTV to PTV margin 
was added for IMPT planning. Figure 1a shows the dose distribution (right panel) as 
well as the contributions of the 3 individual fields. Figure 2a shows the deviation from 
the prescription dose for the nominal scenario (no range error), a range overshoot 
scenario, and a range undershoot scenario. Range errors where modeled by 
upscaling and downscaling the Hounsfield numbers of the planning CT by 4.6%. 
Figure 2a illustrates that range errors do not simply lead to underdose at the edge of 
the CTV that could be compensated for by larger margins. Instead, range errors lead 
to hot spots and cold spots inside the target volume. The reason becomes apparent 
in figure 1a. A range error leads to a relative shift of the dose contributions, which 
consequently do not add up to the planned homogeneous target dose. For a range 
undershoot, an over-proportionate amount of dose is shifted back into the CTV. This 
leads to hot spots, which may be undesirable in those parts of the CTV that contain 
critical normal tissues such as the brainstem. For a range overshoot, an over-
proportionate amount of dose is shifted out of the CTV, which causes cold spots in 
the CTV. The cause of such degradations of the dose distribution lies in the steep 
dose gradients in the dose contributions of individual fields. These are not influenced 
by adding larger margins, illustrating the need for new approaches to account for 
uncertainty. 
 
 
 
 
Figure 1: IMPT plans for an ependymoma patient in whom the target volume 
involves parts of the brainstem. The patient is treated with 3 posterior oblique 
beams. Pencil beams of approximately 3-5 mm sigma are assumed, corresponding 
to the latest generation of proton therapy machines. Shown is the dose distribution 
(right panel) and the dose contributions of the 3 beams. (a) conventional IMPT plan 
created based on a 2 mm CTV to PTV expansion. (b) robustly optimized plan 
accounting for range uncertainty. (c) LET re-optimized plan obtained after minimizing 
LET x dose in the brainstem while constraining the dose distribution to remain close 
to the conventional plan.   
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Figure 2: Robustness analysis of the treatment plans in figure 1a and 1b. Shown is 
the overdose and underdose in percent of the prescription dose for the nominal 
scenario (no range error), range overshoot, and range undershoot.   
 
 
In addition to this fundamental limitation, there are other shortcomings of the PTV 
concept in IMPT. For example, range uncertainties may vary across beam directions 
depending on depth of the target and the traversed tissue. However, IMPT optimizes 
all beam directions simultaneously based on their cumulative dose. Hence a joint 
target volume must be defined with limited possibilities to define beam specific 
margins.  
 
The single field uniform dose (SFUD) technique is a widely-used heuristic to 
counteract the problem related to steep dose gradients in individual fields and dose 
degradation due to misalignment of beams [10].  SFUD treatments typically yield 
more robust plans than IMPT treatments with highly modulated fields. However, the 
use of a PTV together with SFUD still has several limitations. SFUD treatments 
sacrifice some of IMPT's potential to yield optimal plan quality in terms of OAR 
sparing, conformity, and minimization of integral normal tissue dose. Especially for 
complex shaped target volumes that wrap around OARs, SFUD treatments may lead 
to high doses delivered to OARs.  
 
Numerous efforts are underway to reduce range uncertainties. For instance, image-
guided radiation therapy, improved patient immobilization, adaptive planning 
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techniques, and Monte Carlo based dose calculations are being developed. While 
these efforts may reduce required margins, there will always remain residual 
uncertainties. 
 
 
1.2 Biological uncertainties 
 
An additional uncertainty unique to heavy charged particle therapy stems from the 
assumption that the difference in biological effect between protons and photons is a 
constant, i.e. the Relative Biological Effectiveness (RBE) is defined as 1.1. The 
majority of measured RBE values use clonogenic cell survival in vitro as the 
endpoint. The relevance of these for clinical endpoints, particularly for normal tissue 
toxicities, is unclear. Nevertheless, cell survival experiments suggest that the RBE is 
not constant but increases towards the end of range [16]. It is generally assumed 
that the RBE increase with depth reflects an increase of RBE with linear energy 
transfer (LET). Therefore, most RBE models describe RBE as a function of dose, 
LET, and tissue specific parameters.  
 
The distribution of LET in the target volume is typically not homogeneous even if the 
physical dose distribution is homogeneous, especially for highly modulated fields in 
IMPT. Therefore, LET dependence of RBE means that a homogeneous physical 
dose distribution corresponds to an inhomogeneous RBE-weighted dose distribution. 
Furthermore, large uncertainty in RBE models (i.e. how exactly RBE depends on 
dose, LET, and tissue parameters) causes substantial uncertainty in RBE-weighted 
dose.  
 
Most proton RBE models are derived from the linear-quadratic cell survival model 
and use the α/β-ratio as tissue specific parameters [17-20]. It is assumed that tissues 
with low α/β show a larger increase of RBE with LET compared to tissues with high 
α/β. These models have in common that they effectively describe an approximately 
linear increase of RBE with LET. Hence, the biological dose b (i.e. RBE-weighted 
dose) can to first approximation be written as 
 𝑏 = RBE∙𝑑 = (𝑐& + 𝑐(LET) ∙ 𝑑 
 
Here, 𝑐& and 𝑐( are parameters, which are uncertain, and which may depend on 
tissue type and prescription dose level. This equation contains the case of a constant 
RBE of 1.1, corresponding to the parameter values 𝑐& = 1.1 and 𝑐( = 0.  
 
The above equation suggests that the product of LET and dose (LET x dose), 
multiplied by a constant 𝑐(, can be interpreted as the biological extra dose that can 
be attributed to high LET. In current practice, the physical dose distribution is the 
only physical quantity to characterize the quality of a treatment plan. In proton 
therapy, the product of LET and dose can be used as a second physical quantity to 
characterize a treatment plan. One advantage of using LET x dose as a surrogate for 
RBE is that it’s a pure physical quantity. It can be calculated quite accurately based 
on the treatment plan information [21] and does not depend on RBE model 
parameters. A quantitative interpretation of LET x dose requires scaling with the 
parameter 𝑐(, which is highly uncertain. Nevertheless, it is an indicator for local 
increase or decrease of RBE-weighted dose. 
  
 
Figure 3: Distribution of the product of LET and dose (LET x dose) for (a) the 
conventional IMPT plan in figure 1a and (b) the LET re-optimized plan in figure 1c. 
 
 
Figure 3a shows the distribution of LET x dose, scaled by 𝑐( = 0.04	μm/keV, for the 
treatment plan in figure 1a. This parameter value yields an RBE of 1.1 in the center 
of 5 cm spread out Bragg beak for 𝑐& = 0. The figure illustrates that high LET x dose 
is predominantly observed at the edge of the target and that comparatively low 
values are observed in the center. In particular, high values of LET x dose are 
observed in the part of the brainstem that overlaps with the CTV. Hence, uncertainty 
in the knowledge on how much RBE increases with LET (parameter 𝑐() bears the 
risk that normal tissues within or near the target volume are overdosed biologically 
even though physical dose constraints are fulfilled. Likewise, regions of very low LET 
in the tumor may correspond to regions where RBE is lower than 1.1 so that these 
parts of the target receive a dose lower than intended. 
 
This result shown in figure 2a is again explained by considering the dose 
contributions of individual fields in figure 1a. The regions of high LET x dose 
correspond to regions where most of the dose is delivered using the Bragg peak 
rather than the entrance region of the beam. Similar to the case of range uncertainty, 
it is clear that this problem cannot be resolved by applying margins. Instead, LET or 
RBE effects must be included into IMPT treatment plan optimization directly.   
 
Note that, because RBE increases with depth of a proton beam, RBE uncertainties 
are also a type of range uncertainties [19]. However, while local physical range 
errors as described in section 1.1 can be positive or negative, RBE related range 
errors are positive (i.e. increase the range relative to the planned range) if RBE 
values at the end of range are higher than 1.1 [16].  
 
Potential variations in RBE are typically not considered in proton therapy planning 
although treatment planners may avoid certain beam angles due to concerns in RBE 
variations. This is particularly true if a normal tissue close to the distal dose fall-off 
has a maximum tolerance dose (such as the brainstem, spinal cord, or optic 
pathway). 
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2. Robust optimization for physical uncertainties 
 
Instead of using margins and heuristics like SFUD, range or setup uncertainties can 
be accounted for in IMPT planning in a robust optimization framework [15, 22-29].  
Robust optimization methods incorporate uncertainty directly into the treatment plan 
optimization problem for IMPT. Thereby, robust IMPT optimization methods can 
overcome shortcomings of the PTV concept and improve plan quality compared to 
margin based planning [30].  
 
2.1 Conventional IMPT planning 
 
To explain the idea of robust optimization, we first recall that IMPT planning is 
performed with the help of mathematical optimization algorithms. To that end, IMPT 
planning is formulated as a mathematical optimization problem, which means that 
clinical planning goals are translated into a mathematical description of what a good 
treatment plan is. This is done by defining an objective function f(d), a function of the 
dose distribution d which has a small value for good treatment plans and large 
values for bad treatment plans. IMPT planning is then performed by algorithms that 
find the pencil beam intensities that minimize the objective function f [10]. Formally, 
this is written as  
 
  minimize5 			 						𝑓(𝑑) 
  subject	to       𝑑> = ∑ 𝐷>A𝑥AA  
    	𝑥A ≥ 0 
 
where 𝑑> is the dose in voxel i, 𝑥A is the fluence of pencil beam j and 𝐷>A denotes the 
dose contribution of pencil beam j to voxel i.  
 
2.2 Robust IMPT planning 
 
In this formulation of the IMPT planning problem, geometric uncertainty is modeled 
as uncertainty in the dose-influence matrix 𝐷>A. Typically, it is assumed that the 
treatment machine can accurately deliver the treatment plan as specified by the 
pencil beam intensities 𝑥A, ie. 𝑥A is not uncertain. However, it is uncertain what dose 
distribution the treatment plan yields in the patient. The easiest approach to model 
uncertainty is to assume that different dose-influence matrices 𝐷>AD  may apply. Here, 
s is an index of possible error scenarios. For example, range uncertainty can be 
modeled via an overshoot and an undershoot scenario. The dose-influence matrix 
for an overshoot scenario can be calculated by downscaling of the Hounsfield 
numbers in the planning CT, such that all protons penetrate further into the patient 
compared to the original planning CT. 
 
The next question is how a set of error scenarios can be incorporated into IMPT 
planning. In the robust IMPT planning literature, two approaches predominate: the 
probabilistic approach and the worst-case approach. 
 
The probabilistic approach [15, 24], also referred to as stochastic programming in the 
optimization literature, minimizes a weighted sum of objective functions evaluated for 
all error scenarios. Formally this can be written as 
    
    minimize5 			 						∑ 𝑝D𝑓(𝑑D)D 	 
   subject	to       𝑑>D = ∑ 𝐷>AD 𝑥AA  
    		𝑥A ≥ 0 
 
Here, 𝑝D represent importance weights for the error scenarios. Typically, a high 
weight is given to likely scenarios and a small weight to error scenarios that are 
considered possible but unlikely to occur. The probabilistic approach aims to find a 
treatment plan that yields a good treatment plan for all scenarios, ie. for all possible 
dose distributions 𝑑D, the objective function value 𝑓(𝑑D) should be small. The relative 
importance of different scenarios can be controlled by 𝑝D. 
 
The worst-case approach [26], also referred to as minimax optimization, minimizes 
the maximum of objective functions, taken over all error scenarios. Formally this can 
be written as 
    
    minimize5 			 				max	D 		𝑓(𝑑D)	 
   subject	to     	𝑑>D = ∑ 𝐷>AD 𝑥AA  
    𝑥A ≥ 0 
 
Hence, the worst-case approach determines the IMPT plan that is as good as 
possible for the worst error scenario.  
 
There exist several variations of the worst-case approach to robust planning. In 
many cases, the objective function is a sum of contributions from individual voxels. 
Let us assume that the objective function is given by 𝑓(𝑑D) = ∑ 𝑓>(𝑑>D)> . In the worst-
case method originally suggested in [25], the worst case is determined on a voxel-
by-voxel basis rather than for the composite objective function. 
 
   minimize5 								∑ max	D H𝑓>(𝑑>D)I> 																			 
   subject	to      𝑑>D = ∑ 𝐷>AD 𝑥AA  
    	𝑥A ≥ 0 
 
A typical situation is that 𝑓> is given by quadratic penalty functions for underdosing in 
the tumor and overdosing in OARs with maximum dose constraints. The method can 
then be interpreted as optimization of the worst-case dose distribution, where the 
worst case dose distribution contains, voxel-by-voxel, the worst dose than may occur 
for any error scenario (i.e. the lowest dose in the tumor and the highest dose in 
OARs). 
 
2.3 Illustration of robust optimization for range uncertainty 
 
Below we illustrate robust planning using the probabilistic approach for the 
ependymoma patient shown in figure 1. Robust IMPT planning is based on the CTV 
only and no PTV margin is used. For this example, only range uncertainty is 
considered and is modeled via three scenarios:  
 
1. nominal scenario, i.e. no range error; 
2. range overshoot, modeled by downscaling the Hounsfield numbers by 4.66%; 
3. range undershoot, modeled by upscaling the Hounsfield numbers by 4.66%; 
 
The weights 𝑝D were chosen as 0.5 for the nominal scenario and 0.25 for the 
overshoot and undershoot scenario. This simple model is sufficient to demonstrate 
the main effects of robust optimization to make IMPT plans more resilient to range 
errors. It is most illustrative to analyze the dose distributions that the three fields 
contribute (Figure 1b), and compare these to the conventional IMPT plan (Figure 
1a).   
 
• Robust planning for range uncertainty avoids dose gradients in beam direction 
in the dose contributions of individual beams. As a consequence, shifting 
these dose distributions along the incident beam direction has only a 
moderate impact on the dose distribution in the patient. 
• Robust planning for range uncertainty automatically extends the irradiated 
region distal to the target volume, i.e. it automatically generates the 
appropriate margin necessary to achieve target coverage for the assumed 
range error without the need to manually define PTV margins. 
• Robust planning avoids placing the distal edge of a pencil beam in front of 
OARs. Instead, the lateral falloff is used to shape the dose distribution in the 
region where OAR and target abut.  
 
Figure 2b demonstrates that the treatment plan obtained through robust planning is 
indeed more resilient to range errors compare to the conventional plan. Despite 
range undershoot or overshoot, a homogenous dose distribution is delivered to the 
CTV. 
 
 
2.4 State of research 
 
Robust IMPT optimization has been investigated almost exclusively for range and 
setup uncertainty. The published methods can be categorized into the probabilistic 
approach [15, 24] and different flavors of the worst-case approach: the composite 
worst case [26], the objective-wise worst case [23], and the voxel-wise worst case 
[22, 25]. Since robust planning techniques for IMPT were first investigated, the 
question whether one method is generally superior has been discussed. The 
probabilistic approach optimizes the average plan quality. It is possible that a plan 
does not achieve the desired dose quality for the worst scenario, for example in 
situations where a large number of scenarios  are modeled. On the other hand, the 
minimax approach optimizes the plan for the worst case only and has no incentive to 
improve plan quality for more likely scenarios. It was shown that some methods do 
yield undesirable results in specific situations [31], but there is no comprehensive 
evidence that one method is generally superior. To first approximation, all methods 
achieve the features of robust plans described above if used adequately.  
 
Most prior works have used a small set of discrete range and setup errors to model 
uncertainty [22, 25, 26] or sampled errors from a Gaussian distribution [24]. More 
recently, researchers developed improved methods to quantify dose uncertainty. 
Bangert et al [32] developed analytical methods to calculate expectation value and 
variance of the dose distribution for Gaussian range and setup errors without relying 
on sampling. Perko et al [33] used a technique called polynomial chaos expansion  
to develop a parameterized model of the dose distribution as a function of range and 
setup errors.  
 
 
 
3. Robustness of IMPT plans against biological uncertainties 
 
Robustness against geometric uncertainty is usually understood as ensuring that 
range or setup errors do not lead to overdosing of OARs or underdosing in the 
target. A similar notion of robustness can be applied to uncertainty in RBE. In that 
sense, a robust plan is one that does not cause overdosing of OARs if the RBE is 
higher than expected, or underdosing of the target if RBE is lower than expected. 
However, at this stage, there is no commonly agreed notion of robustness against 
RBE uncertainty.  
 
High LET in critical structures within or near the target volume may potentially lead to 
higher RBE-weighted doses, and thereby increase the risk of side effects. However, 
it has been demonstrated that LET distributions can typically be modified while 
maintaining target prescriptions and normal tissue constraints [34-37] in terms of 
physical dose. An IMPT planning method to make IMPT plans more robust against 
this risk was recently suggested [37]. In this method, an IMPT plan is initially 
optimized based on physical dose (or equivalently, based on a constant RBE of 1.1). 
In a second step, the treatment plan is re-optimized regarding the LET distribution 
with the goal of avoiding high LET in critical structures within or near the target 
volume. During the second step, the physical dose distribution is constrained to 
remain close to the initial treatment plan obtained in the first step. It was shown in 
that LET hotspots in OARs can typically be avoided by accepting very small 
degradations of the physical dose distribution. This method is illustrated in figure 1c 
and 3b. Here, the LET based re-optimization step is applied to the conventional 
IMPT plan shown in figure 1a. We enforced the constraint that target coverage and 
conformity do not worsen, while we allow a small increase of 3% in the brainstem 
gEUD and the mean dose in the normal tissue. The LET re-optimization step aims at 
minimizing the product of LET and dose (LET x dose) in the brainstem. The resulting 
LET x dose distribution is shown in figure 3b, which illustrates that high LET is now 
avoided inside the brainstem. Figure 1c shows how the treatment plan is modified. 
The LET re-optimized plan avoids pencil beams incident from the left (right side of 
the image) that stop in the brainstem. Instead, the fluence of pencil beams incident 
from the right (left side of the image) is increased, which deliver dose to the part of 
the target overlaying the brainstem via the entrance region of the beam.   
 
Some authors have suggested performing IMPT treatment plan optimization based 
on RBE-weighted dose [38, 39]. In this case, IMPT planning is performed by 
evaluating the objective function f for biological dose rather than physical dose as in 
conventional IMPT planning. For the simplified linear RBE model considered above 
(and analogously for any other RBE model), this can formally be written as 
 
             minimize5 			 				𝑓(𝑏) 
   subject	to     	𝑏> = 𝑐&𝑑> + 𝑐(𝐿>𝑑> 
     𝑑> = ∑ 𝐷>A𝑥AA  
     𝐿> = &KL ∑ 𝐿>A𝐷>A𝑥AA  
    𝑥A ≥ 0 
 
Here 𝐿>A is the dose-averaged LET in voxel i for the dose contribution of pencil beam 
j, and 𝐿> is the LET in voxel i averaged over all pencil beams. However, due to 
uncertainty in the RBE model (in this case mostly in the parameter 𝑐() this approach 
is typically considered insufficient and is not applied in practice. RBE-based IMPT 
planning in this pure form would yield treatment plans that are highly non-robust with 
respect to uncertainties in the RBE model parameters. This can best be illustrated 
for the case of target coverage. Suppose an objective function to minimize target 
underdose, such as the standard quadratic penalty function, is evaluated for RBE-
weighted dose. This would yield treatment plans that lower the physical dose 
compared to conventional plans in those parts of the target where the LET is high - 
based on the assumption that RBE is higher than 1.1 in these regions. 
Consequently, these regions would be underdosed if the increase of RBE with LET 
was less than assumed in the RBE model.  
 
This problem can potentially be addressed by applying robust optimization 
techniques to RBE-based IMPT planning. Whereas physical dose uncertainty 
corresponds to uncertainty in the dose-deposition matrix 𝐷>A, uncertainty in the 
biological dose corresponds to uncertainty in the RBE model parameters. Assuming 
that different sets of RBE model parameters (𝑐&D, 𝑐(D) may apply, the stochastic 
programming approach applied to this situation would solve the IMPT planning 
problem 
 
             minimize5 			 				∑ 𝑝D𝑓(𝑏D)D 	 
   subject	to      𝑏>D = 𝑐&D𝑑> + 𝑐(D𝐿>𝑑> 
      𝑑> = ∑ 𝐷>A𝑥AA  
     𝐿> = &KL ∑ 𝐿>A𝐷>A𝑥AA  
    𝑥A ≥ 0 
 
To our knowledge, a formal application of robust optimization or stochastic 
programming to handle RBE uncertainties has not been demonstrated yet.   
 
 
4. Discussion 
 
Robust planning in commercial planning systems 
 
Robust planning methods have initially been investigated as a method to incorporate 
organ motion and setup uncertainty in IMRT planning [40-45]. Only a few years later, 
similar concepts were applied to handling range und setup errors in IMPT. The 
fundamental limitations of the PTV concept in IMPT as described in section 1.1 led to 
the first implementations of robust planning methods in commercial TPS. Today, 
several vendors provide robust planning for proton therapy. Interestingly, these 
implementations cover all three methods described in section 2.2. Raystation 
provided the first commercial solution and has an implementation of the composite 
worst-case method; Pinnacle uses the probabilistic approach; and Eclipse follows 
the voxel-wise worst case method. Robust optimization methods for range and setup 
uncertainty should allow the transition from a research topic to a methodology that is 
available in clinical practice. This will give a broader group of practitioners the ability 
to evaluate these methods and develop practical guidelines on how to best use 
them.  
 
Treatment plan evaluation for IMPT 
 
The fundamental assumption behind the PTV concept is that, as long as the CTV 
moves within the boundaries of the PTV, and the PTV is irradiated to the prescribed 
dose, then the CTV is guaranteed to receive the prescribed dose. The assumption is 
not generally valid for IMPT because misalignment of the dose contributions for 
highly modulated fields may cause dose degradation anywhere inside the target 
volume. As a consequence, treatment plan evaluation for IMPT (especially for highly 
modulated fields) should explicitly consider the dose distributions evaluated for a set 
of range and setup errors. Most planning systems now have the capability to perform 
this in a convenient manner.  
 
Robust planning for biological uncertainties 
 
Robust planning methods to address RBE uncertainties are less developed than 
robust planning methods for physical uncertainty. A possible next step towards that 
goal may be to use the product of LET and dose as a second quantity (besides 
physical dose) to evaluate and create a treatment plan. LET x dose has several 
advantages in that regard: 
 
• It is a well defined physical quantity that (unlike RBE) does not depend on any 
model parameters. Monte-Carlo dose calculation algorithms yield LET x dose 
at almost no additional computational cost, and also pencil beam algorithms 
can provide sufficient approximations. 
• LET x dose can to first approximation be interpreted as a measure of the 
biological extra dose that comes for elevated LET, up to the scaling factor 𝑐(. 
Hence, LET x dose is more accessible to a quantitative interpretation 
compared to LET itself. 
• From a technical perspective, LET x dose has the advantage that it is a linear 
function of pencil beam fluence. Therefore, the same optimization algorithms 
that are well established for physical dose optimization can be applied.  
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